Daniel Reinhorn

Dr. Daniel Reinhorn

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2021 in The Breast
Verified
Journal Article
Open access
DRDaniel Reinhorn
Daniel Reinhorn
RMRaz Mutai
Raz Mutai
RYRinat Yerushalmi
Rinat Yerushalmi
AMAssaf Moore
Assaf Moore
EAEitan Amir
Eitan Amir
HGHadar Goldvaser
Hadar Goldvaser
Locoregional therapy (LRT) in de novo metastatic disease is controversial with inconsistent results from randomized control trials (RCTs). RCTs comparing LRT and systemic therapy to standard therapy alone in de novo metastatic breast cancer were identified. Hazard ratios (HRs) and their associated 95% confidence intervals (CIs) were computed and pooled in a meta-analysis using generic inverse variance. Overall survival (OS) and time to locoregional progression data were extracted for the intention to treat (ITT) population. Data on OS for pre-specified subgroups defined by tumor subtype and by site of metastases were also extracted. Analyses included 4 trials comprising 970 patients. LRT included standard surgery to the primary breast tumor in all studies, and adjuvant radiation per standard of care was required in 3 studies. Compared to standard treatment, LRT was not associated with improved OS in the ITT population (HR 0.97, 95% CI 0.72-1.29, p = 0.81). However, LRT was associated with improved time to locoregional progression (HR 0.36, 95% CI 0.14-0.95, p = 0.04). LRT was not associated with improved OS in any tumor subtypes, including hormone receptor positive (HR 0.96, 95% CI 0.65-1.43), triple negative (HR 1.4, 95% CI 0.50-3.91) and human epidermal growth factor receptor 2 positive disease (HR 0.93, 95% CI 0.68-1.28). Additionally, LRT did not improve OS in bone only disease (HR 0.97, 95% CI 0.58-1.62) and in visceral disease (HR = 1.02, 95% CI 0.77-1.35). Our critical appraisal has identified some methodological problems in the design and conduct of the studies included that could affect the meta-analysis result. LRT in de novo metastatic breast cancer is not associated with improved OS. Results are consistent among different breast cancer subgroups. However, this conclusion should be interpreted with caution in view of the limitations identified in meta-analysis.

19 March 2020 in Immunotherapy
Verified
Journal Article
Closed access
DRDaniel Reinhorn
Daniel Reinhorn
OJOded Jacobi
Oded Jacobi
OIOded Icht
Oded Icht
Elizabeth DudnikElizabeth Dudnik
Elizabeth Dudnik
OROfer Rotem
Ofer Rotem
DGDaniel A. Goldstein
Daniel A. Goldstein
Aim: The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). It is common practice to continue treatment beyond progression (TBP) in selected cases. The aim of this study was to evaluate real life practice and outcomes related to TBP. Materials & methods: We retrospectively evaluated advanced non-small-cell lung cancer patients treated with ICI therapy and identified patients who were treated beyond progression. Results: Of 207 patients included in this analysis, 22% patients received TBP. A total of 36% achieved a clinical benefit. A total of 27% patients had a progression-free interval over 6 months after receiving TBP. Conclusion: A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.

1 March 2022 in Clinical Lung Cancer
Verified
Journal Article
Closed access
LHLiran Holtzman
Liran Holtzman
MMMor Moskovitz
Mor Moskovitz
DUDamien Urban
Damien Urban
HNHovav Nechushtan
Hovav Nechushtan
SKShoshana Keren
Shoshana Keren
Elizabeth DudnikElizabeth Dudnik
Elizabeth Dudnik

15 March 2025 in Cancer
Verified
Journal Article
Closed access
DRDaniel Reinhorn
Daniel Reinhorn
MMMor Moskovitz
Mor Moskovitz
WTWilliam D. Tap
William D. Tap
BLBob T. Li
Bob T. Li

27 March 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
DRDaniel Reinhorn
Daniel Reinhorn
IKIryna Kuchuk
Iryna Kuchuk
TSTzippy Shochat
Tzippy Shochat
BNBella Nisenbaum
Bella Nisenbaum
ASAaron Sulkes
Aaron Sulkes
RYRinat Yerushalmi
Rinat Yerushalmi

7 February 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
IAItamar Averbuch
Itamar Averbuch
RTRoi Tschernichovsky
Roi Tschernichovsky
SYShlomit Yust-Katz
Shlomit Yust-Katz
OROfer Rotem
Ofer Rotem
DLDror Limon
Dror Limon
OGOmer Gal
Omer Gal
Introduction: Historically, patients with brain metastasis (BM) have been excluded from clinical trials investigating treatments for non-small cell lung cancer (NSCLC) due to their unfavorable prognosis. Advanced treatments have increased survival prospects for NSCLC patients with BM. This study evaluated the life expectancy of NSCLC patients with and without BM in the context of contemporary treatments. Methods: Outcome data were collected for patients with advanced NSCLC attending a tertiary medical center between 2015 and 2020. Patients were stratified according to BM status and compared for overall survival (OS) using log-rank and Cox regression analyses. Results: The cohort included 360 patients with NSCLC of whom 134 (37.2%) had BM. Most (95%) of cases of BM developed within the first two years: 63% at diagnosis, 18% during the first year, 14% during the second year. There was no significant difference in OS between patients without BM and those with BM (median 23.7 vs. 22.3 months, HR = 0.97, p = 0.82); patients with BM and a targetable or non-targetable mutation (40.2 vs. 31.4 months, HR = 0.93, p = 0.84, and 20.7 vs. 19.87 months, HR = 0.95, p = 0.75, respectively); and patients with symptomatic BM (23.7 vs. 19.8 months, HR = 0.95, p = 0.78). Treatment for BM (95% of patients) consisted of stereotactic radiosurgery or tyrosine kinase inhibitors, with corresponding intracranial control rates of 90% and 86%. Conclusion: The results imply that the presence of BM has no impact on the prognosis of NSCLC. The practice of excluding NSCLC patients with BM from clinical trials warrants reconsideration.